Appili Therapeutics Inc. (APLI.TO)

CAD 0.04

(-12.5%)

Market Cap (In CAD)

4.24 Million

Revenue (In CAD)

827.4 Thousand

Net Income (In CAD)

-3.78 Million

Avg. Volume

89.6 Thousand

Currency
CAD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.025-0.06
PE
-
EPS
-
Beta Value
0.971
ISIN
CA03783R1073
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Donald D. Cilla Jr., M.B.A., Pharmd
Employee Count
-
Website
https://www.appilitherapeutics.com
Ipo Date
2019-06-25
Details
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.